Seres Plans Deep Dive After Microbiome Drug Fails In Ulcerative Colitis Trial

 
• By Alaric DeArment

The company plans an intensive review to determine the path forward for SER-287. A similar deep dive led to the successful revival of its C. difficile drug, SER-109, which it plans to submit for approval.

Bacterias 3D rendering
Seres will do a deep dive into data from its failed Phase IIb study of SER-287 in ulcerative colitis • Source: Shutterstock

More from Clinical Trials

More from R&D